Introduction
Breast tumor formation and progression involve complex interactions between tumor cells and their surrounding environment. Infiltration of immune cells into the tumor microenvironment has been linked to tumor formation and progression (1) . Specifically, increased numbers of tumor associated macrophages are linked to poor prognosis in breast cancer patients (2) . While macrophages were initially expected to inhibit tumor growth via their cytotoxic functions, it is now clear that exposure to the tumor microenvironment polarizes macrophages towards a tumor-promoting phenotype (3) . Therefore, obtaining a better understanding of the mechanisms through which macrophages regulate tumor growth and progression may result in the development of strategies that either inhibit the activities of tumorpromoting macrophages or re-program the macrophages to increase their tumor cytotoxic activities. Numerous functions have been ascribed to macrophages during tumor progression, including promotion of tumor cell invasion, angiogenesis and immune suppression (4) . While published studies have identified specific mechanisms through which macrophages contribute to mammary tumor metastasis in mouse models (5, 6) , less is known regarding the mechanisms of macrophage function during mammary tumor initiation.
Macrophages associated with late stage tumors have been shown to express high levels of transforming growth factor-beta (TGFβ) (7) . TGFβ, which is a key regulator of development, immune function and wound healing, acts primarily through a core signaling pathway involving the Smad family of transcription factors (8) . During mammary gland development, TGFβ is a potent inhibitor of epithelial cell proliferation and branching morphogenesis (9) . In premalignant lesions, TGFβ acts as a tumor suppressor by inhibiting proliferation and promoting apoptosis.
Paradoxically, malignant tumors are associated with high levels of TGFβ, which promote later stages of tumor progression and metastasis (8, 10) . Pleiotropic effects of TGFβ have also been observed in macrophages, depending on their stage of differentiation. While TGFβ acts as a chemoattractant for monocytes, it inhibits phagocytosis and production of proinflammatory 4 mediators in differentiated macrophages (11) . TGFβ expression levels are high in macrophages associated with late stage tumors (7) , which is thought to influence many aspects of malignant progression including invasion, angiogenesis and immune suppression (10) . However, the functional consequences of regulating the TGFβ/Smad signaling pathway within macrophages during different stages of tumorigenesis have not been investigated.
Inappropriate activation of growth factor signaling pathways has been strongly linked to breast cancer formation and progression. Recent studies have implicated the fibroblast growth factor (FGF) pathway in tumor growth, progression and resistance to standard therapies (12, 13) . Amplification of the chromosomal region of 8p12 that includes the FGF receptor 1 (FGFR1) gene is associated with poor prognosis, and approximately 10% of breast cancers exhibit amplified FGFR1 (13, 14) . Transgenic mice expressing an inducible FGFR1 (iFGFR1) transgene in mammary epithelial cells develop early epithelial lesions that progress to alveolar hyperplasia, ultimately resulting in mammary tumor formation (15) . Activation of iFGFR1 leads to alterations in the microenvironment, including increased angiogenesis and a rapid inflammatory response characterized by infiltrating macrophages (15, 16) . Macrophage depletion in this model leads to reduced epithelial cell proliferation and angiogenesis associated with early stage lesions demonstrating that in an FGFR1-dependent model of mammary tumor formation, macrophages are capable of promoting the development of early stage epithelial lesions (16) .
In these studies, we have further utilized the iFGFR1 model to identify mechanisms that regulate the pro-tumor functions of macrophages during early stage tumor formation. We demonstrate here that macrophages associated with iFGFR1-driven early stage epithelial lesions exhibit decreased activation of the TGFβ/Smad3 pathway. The decrease in TGFβ-associated genes within macrophages correlates with increased expression of macrophagederived chemokines that bind to the chemokine receptor Cxcr2. Restoration of TGFβ signaling leads to inhibition of expression of these chemokines in macrophages. These studies suggest 
Materials and Methods
Animals. Generation of mouse mammary tumor virus (MMTV)-iFGFR1 transgenic mice has been described previously (15) and the mice were obtained from Dr. Jeffrey Rosen (Baylor College of Medicine, Houston, TX, USA). Animal care and procedures were approved by the Institutional Animal Care and Use Committee of the University of Minnesota and were in accordance with the procedures detailed in the Guide for Care and Use of Laboratory Animals.
Cell sorting and RT-PCR analysis. Six-week-old female MMTV-iFGFR1 transgenic mice and non-transgenic littermates were injected intraperitoneally (i.p.) with 1 mg/kg B/B dimerizer (Clontech, Mountain View, CA, USA). Mice were sacrificed 48 hours later and mammary glands were collected for analysis. The tissue was dissociated using 2 mg/ml collagenase A (Roche Applied Science, Indianapolis, IN, USA) for 45 minutes at 37°C with rocking at 200 rpm. The solutions were vigorously shaken every 15 minutes and the dissociated cells were collected by centrifuging for 5 minutes at 1500 rpm. The cells were washed 3 times with DMEM/F12 containing 5% fetal bovine serum (FBS) at 1500 rpm and 2 times at 800 rpm for 5 minutes each.
The cells were stained with either Cd11b-APC (Life Technologies, Grand Island, NY, USA) at a dilution of 1:200 or isotype control antibody at the same concentration for 1 hour at RT. The cells were then washed, filtered through a 40 micron filter and sorted using a triple laser MoFlo (Cytomation, Fort Collins, CO, USA). RNA was isolated from Cd11b-positive cells sorted from 6 mice per timepoint as described above and pooled into duplicate samples. RNA was extracted 6 using the Arcturus PicoPure RNA Isolation Kit (Life Technologies) and RT-PCR analysis was performed using primers specific for ArgI and iNOS as described below. qRT-PCR analysis was performed for TGFβ1 as described below. Primer sequences are listed in Supplemental Table 1 .
Cyclophilin was used to normalize gene expression levels.
Immunohistochemistry and immunofluorescence. Mammary glands from MMTV-iFGFR1 transgenic mice, or non-transgenic littermate controls, that were treated with B/B for 48 hours as described above were fixed for 2 hours in 4% paraformaldehyde and embedded in paraffin. Five micron sections were used for immunohistochemistry and immunofluorescent staining using the following antibodies and dilutions: rat monoclonal F4/80 (Invitrogen, Carlsbad, CA, USA), 1:50; phospho-Smad3 (Cell Signaling, Danvers, MA, USA), 1:200. Immunostaining was performed as described previously (17) in the absence of antigen retrieval. F4/80 and phospho-Smad3 positive cells were counted and double positive cells were calculated relative to the total number of F4/80 positive cells. A minimum of 600 cells from a total of three mice per treatment group was counted for each dataset. All statistical analyses were performed using the unpaired student's t-test to compare two means.
Cell culture. HC-11 cells were maintained in RPMI containing 10% FBS (Invitrogen), 1% penicillin-streptomycin, 5 μg/ml insulin (Sigma-Aldrich, St. Louis, MO) and 10 ng/ml epidermal growth factor (EGF) (Invitrogen). HC-11 cells stably expressing the iFGFR construct (HC-11/R1) were generated as previously described (18) and were acquired from Dr. Jeffrey Rosen. HC-11/R1 cells were maintained in HC-11 medium with the addition of 0.7 μg/ml puromycin (SigmaAldrich). We received SUM225 and MCF10DCIS.com from Dr. Fariba Behbod (University of Kansas City Medical Center, Kansas City, KS, USA) and maintained as described (19) . Table 1 .
qRT-PCR Array. RNA was isolated from RAW 264.7 cells treated with R1-CM for 2 hours in the presence and absence of 10 ng/ml TGFβ, and cDNA was made, as described above. The Cell Signaling) and ERK1/2 (sc-94; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Three-dimensional co-culture assay. Mammary glands were isolated from 8-12 week old MMTV-iFGFR1 transgenic mice as described above. Bone marrow was collected from femurs of 6-10 week old wild-type mice. Cells were differentiated into macrophages with the addition of 20% conditioned media from L929 cells that have a high concentration of granulocyte colonystimulating factor (G-CSF). 10,000 mammary epithelial cells (MECs) were plated on growthfactor reduced matrigel (BD Biosciences) in 8 well chamber slides as described previously (21) After 2 days, 3000 bone marrow derived macrophages (BMDM) were added to the 3D culture. antifade reagent with DAPI (Invitrogen). Images were taken at confocal microscopy facility at the Masonic Cancer Center (University of Minnesota, Minneapolis, MN).
Results

Regulation of pro-and anti-inflammatory genes in macrophages following
exposure to conditioned media from iFGFR1-activated HC-11/R1 cells. As described previously, activation of iFGFR1 in mammary epithelial cells promotes rapid recruitment of macrophages to epithelial structures in vivo and in vitro (16) . Furthermore, depletion of macrophages leads to delayed formation of early hyperplastic lesions in vivo (16) . Therefore, we further utilized this model to delineate the mechanisms that mediate the interactions between epithelial cells and macrophages. We have previously shown that exposure of macrophages to conditioned media from HC-11/R1 cells following activation of iFGFR1 leads to increased production of the proinflammatory cytokine IL-1β by macrophages in vitro and that IL-1β contributes to the formation of early stage lesions in vivo (17) . To extend our analysis of macrophage response to iFGFR1 activation in epithelial cells, we further analyzed the expression of various genes known to be preferentially regulated in tumor associated macrophages, including IL-10, IL-12, Arginase I (ArgI) and TGFβ. For these studies, RAW 264.7 cells were exposed to conditioned media from HC-11/R1 cells treated with either the B/B homodimerizer, which activates the iFGFR1, or ethanol as a solvent control. After exposure to conditioned media, RAW 254.7 cells were analyzed for expression and activity of Arg1, IL-10, IL-12 and TGFβ. As shown in Figure 1A and 1B, expression levels of IL-10 and gene expression and activity of ArgI, which are typically increased in tumor associated macrophages, were induced whereas expression levels of IL-12, which are normally reduced in tumor associated macrophages, were decreased. Interestingly, expression of the TGFβ1 gene, which is usually induced in tumor associated macrophages, was reduced in these studies. In addition, the transcriptional activity of Smad3 also decreased ( Figure 1D ) suggesting an overall decrease in the TGFβ/Smad3 pathway. These results, together with our previously published studies (17) , 
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TGFβ combined, we focused on genes in cluster 1, which were up-regulated with B/B treatment and down-regulated with the addition of TGFβ. Interestingly, 4 of these chemokines (Cxcl1, Cxcl2, Cxcl5, and Cxcl7) are ligands for the Cxcr2 receptor. Before validating expression levels of these chemokines, we confirmed that Cxcr2 is expressed in the HC-11 mammary epithelial cell line by immunoblot analysis ( Figure 3A) . We validated the results from the array using distinct primer sets to determine gene expression and ELISAs to measure secreted proteins.
We observed similar gene and protein expression patterns for both Cxcl1 and Cxcl5 ( Figure   3B ). Induction of Cxcl2 and Cxcl7 was not detected by ELISA (data not shown). These data suggest that macrophages respond to FGFR1-induced soluble factors by increasing the production of chemokines that bind Cxcr2, primarily Cxcl1 and Cxcl5, and that this induction can be inhibited by restoring TGFβ signaling.
Next, we wanted to determine the signaling pathway by which the Cxcr2 ligands are regulated in the macrophages. Expression of Cxcr2 ligands can be regulated by various signaling pathways depending on cell type and stimulus, including the NFκB and ERK pathways (24, 25) . Interestingly, we were unable to detect an increase in NFκB activity in macrophages exposed to conditioned media from B/B-treated HC-11/R1 cells (data not shown). Further analysis focused on examining the ERK signaling pathway. For these studies, RAW 264.7 cells were exposed to conditioned media from HC-11/R1 cells treated with or without B/B. Protein lysates were collected at different time points and the expression of phosphorylated and total ERK1/2 was examined. There was a rapid induction of ERK1/2 activation in macrophages treated with B/B conditioned media in comparison to solvent controls ( Figure 3C ). Further studies were performed to determine the contribution of the ERK1/2 pathway to expression of the Cxcr2 ligands. As shown in Figure 3D , blocking ERK activation with the MEK1 inhibitor U0126 led to a decrease in gene expression of the Cxcr2 ligands. Inhibition of Cxcl1 was observed at the lowest concentration of U0126, whereas there was a dose-dependent decrease Figure 3D ). These results suggest that although both ligands are regulated by the ERK pathway, they may be regulated via slightly different mechanisms. Overall, these results indicate that the ERK pathway contributes to the regulation of Cxcr2 ligand expression.
Macrophages induce migration of epithelial cells, which is blocked by Cxcr2
inhibition. To determine the effects of Cxcr2 ligand secretion from macrophages, we developed a co-culture migration assay ( Figure 4A ). In this assay, conditioned medium from the HC-11/R1 cells containing FGFR1-induced soluble factors was added to RAW 264.7 cells and allowed to incubate overnight. The ability of the soluble factors collected from the treated RAW 264.7 cells to promote migration of parental HC-11 cells, which do not respond to B/B treatment, was determined using a transwell assay. The ability of macrophages to promote epithelial cell migration following exposure to conditioned media from cells with an activated FGFR1 reflects the ability of the stimulated macrophages to act in a tumor-promoting manner. Conditioned media from B/B treated HC-11/R1 cells alone was able to induce migration of HC-11 cells, suggesting that activation of FGFR1 in these cells leads to the production of migratory factors ( Figure 4B ). However, the conditioned media isolated from the treated macrophages led to a significant increase in migration of HC-11 cells compared with conditioned media from the HC-11/R1 cells alone ( Figure 4B ). Therefore, treatment of macrophages with conditioned media following FGFR1 activation leads to an increase in the ability of macrophages to produce migratory factors. To determine whether the increase in migration required Cxcr2, we further assessed the effects of blocking Cxcr2 activity on HC-11 cell migration using the Cxcr2-specific inhibitor SB225002. As shown in Figure 4B , the increase in migration was blocked when conditioned media was added to the human monocyte cell line THP-1 that had been differentiated to macrophages with PMA as described (27) . After 2 and 4 hours, THP-1 cells were collected for gene expression analysis. In addition to the Cxcr2 ligands in mice, human cells also express CXCL8. Gene expression of all CXCR2 ligands, with the exception of CXCL7 (data not shown), increased following exposure to conditioned media from MCF-7 cells treated with bFGF ( Figure 6B ). Further analysis of protein expression demonstrated significant increases in secretion of both CXCL1 and CXCL8 (Figure 6B ), while the other ligands were not expressed at detectable levels by ELISA (data not shown). bFGF treatment of THP-1 cells alone did not induce expression of these chemokines, suggesting that these results are not due to the direct action of bFGF on macrophages (data not shown). The MCF-7/THP-1 conditioned media was used as the chemoattractant in a transwell migration assay to examine the migration of MCF-7 cells. Media from MCF-7 cells exposed to bFGF increased migration compared to no treatment and there was an additional increase when the media was also exposed to THP-1 cells ( Figure 6C ). Finally, migration was inhibited with a CXCR2 inhibitor ( Figure 6C 
chemokines. An inverse correlation between the TGFβ pathway and expression of inflammatory chemokines has been observed in other studies. For example, decreased TGFβ responsiveness in prostatic fibroblasts caused an upregulation of chemokines including CXCL1, leading to the adhesion of prostate cells to the bone matrix (31) . Also, loss of TGFβ signaling in mammary fibroblasts resulted in increased production of the proinflammatory chemokine Ccl2, which contributed to growth and metastasis of 4T1 mammary tumors (32) . In addition, recent studies using a mouse model of pancreatic ductal adenocarcinoma also demonstrated an increase in Cxcr2 ligands associated with loss of Tgfbr2 in the pancreas (24) . Interestingly, these studies demonstrated that induction of the Cxcr2 ligands was dependent on the NFκB pathway, whereas induction in macrophages in our model is dependent upon the ERK signaling pathway. These results possibly represent cell-type specific differences in CXCR2 ligand regulation. Taken together, our results, along with published studies, demonstrate that decreased TGFβ signaling is associated with increased expression of inflammatory chemokines, and that these chemokines are capable of contributing to tumor formation and progression.
Interactions between chemokines and chemokine receptors are known to contribute to breast cancer progression (33) . Recent studies have implicated CXCR2 and its various ligands in breast cancer. A number of studies have focused on CXCL8, also known as IL-8, which binds to both CXCR1 and CXCR2 and appears to be the primary CXCR2 binding chemokine induced in response to bFGF-treated breast cancer cells ( Figure 6B ). Expression of CXCL8 has been linked to increased tumor grade and experimental studies have demonstrated its ability to regulate angiogenesis and tumor progression (33) (34) (35) . CXCR2 expression itself has been detected on breast cancer cells (34) and inhibition of CXCR2 decreased mammary tumor cell invasion in vitro (36) . Furthermore, knock-down of CXCR2 in metastatic mammary tumor cells led to decreased metastasis in orthotopic transplantation models (36) . The CXCR2 ligand CXCL3 was identified in a screen for genes associated with basal-like breast cancers and a 
CXCR2 inhibitor was shown to decrease viability of basal-like breast cancer cell lines in vitro (37). Furthermore, polymorphisms in the CXCR2 gene have been identified in breast cancer patients and these polymorphisms correlated with larger tumor size, higher tumor grade and increased lymph node metastasis (38) . However, the functional consequences of this polymorphism on CXCR2 expression and/or activity remain to be determined. Our studies demonstrate that activation of epithelial cell-specific CXCR2 by chemokine-producing cells within the tumor stroma may play a role in early stages of tumorigenesis. Taken together, these studies suggest that the CXCR2 axis may represent a viable pathway to target during both early and late stage tumor development.
Our studies have focused on the use of mammary epithelial cells expressing an iFGFR1 construct. To demonstrate that the results were not specific to the iFGFR1 model, we validated our results using the MCF-7 cell line, which has been previously used to study endogenous FGF signaling (26, 39, 40) . Similar to the results obtained with the iFGFR1 model, activation of the FGF signaling pathway in MCF-7 cells also led to an increase in CXCR2 ligand gene expression in macrophages. Interestingly, FGFR1 activity has been shown to promote resistance of estrogen receptor positive breast cancer cells to endocrine-based therapies (13) . Although it has been reported that estrogen receptor positive cells, including MCF-7, express lower levels of CXCR2 than more invasive breast cancer cell lines (34) , our studies as well as another report (41) In summary, our studies have focused on the effects of tumor cell-specific FGFR1 activation on alterations within the tumor microenvironment. We have previously demonstrated a rapid inflammatory response characterized by recruitment of macrophages to the epithelial structures (16) . We have also demonstrated that anti-inflammatory drugs are capable of inhibiting the initiation of FGFR1-driven epithelial lesions, demonstrating that inflammation is an important promoter of FGFR1-driven tumorigenesis (17) . Using the iFGFR1 model, we have developed novel co-culture models to identify specifically how FGFR1-driven tumor cells communicate with the microenvironment. We have identified a paracrine mechanism in which soluble factors from the FGFR1-activated cells lead to increased production of CXCR2 ligands, which then feed back to promote migration and invasion of the tumor cells. Importantly, these findings were validated using an FGF-responsive breast cancer cell line, demonstrating that 
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